TOP > 外国特許検索 > BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE

BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE NEW

外国特許コード F200010180
整理番号 (S2018-0779-N0)
掲載日 2020年7月27日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP027907
国際公開番号 WO 2020017496
国際出願日 令和元年7月16日(2019.7.16)
国際公開日 令和2年1月23日(2020.1.23)
優先権データ
  • 特願2018-134042 (2018.7.17) JP
  • 特願2018-169209 (2018.9.10) JP
発明の名称 (英語) BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE NEW
発明の概要(英語) The purpose of the present invention is to provide a novel blood-brain barrier permeable peptide. The present invention provides a blood-brain barrier permeable peptide including the amino acid sequence SLSHSPQ (SEQ ID NO: 1) (where P may be substituted). The present invention also provides: a carrier molecule that is for delivery to the brain and that contains the peptide; a complex of the peptide and a molecule of interest that is to be passed through the blood-brain barrier; and a blood-brain barrier permeable composition including the complex.
従来技術、競合技術の概要(英語) BACKGROUND ART
Central nervous system diseases in order to maximize the efficacy of a therapeutic agent is, the drug needs to be efficiently delivered to the brain. However, blood is administered or diffused water-soluble drug and protein, most of the brain known to not be migrated. This is because, the BBB, blood brain barrier separating the tissue fluid functions as the physical and dynamic, into the brain of the material of the passive diffusion is so strictly limited. Therefore, the target substance is administered to the blood in the brain is delivered, the BBB efficiently transmit the carrier molecule is essential for development.
Water-soluble drugs and proteins in the brain such as brain material does not shift to the carrier for delivery of the molecule have been reported. To this, in the brain through the BBB to the delivery of the drug, the pharmaceutical order to improve the transmittance of the BBB, BBB expressing the transferrin receptor monoclonal antibody (JCR (registered trademark) manufactured by J-Brain Cargo), insulin receptor monoclonal antibody or antibody transmissive BBB FC5, Tat 1 peptide across the cell membrane and one of the RVG-9R peptide, such as RDP or a carrier using the BBB Angiopep Drug Delivery System(DDS) transmission have been developed (Non-Patent Document 1-6). However, the transmission of the existing carrier using the BBB many of the DDS, there is a limit to the size of a substance to be transmitted is a problem. In addition, using an antibody immunogenic DDS also has a problem.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • ITO, Shingo
  • OHTSUKI, Sumio
  • YAMAGUCHI, Shunsuke
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close